Adagene (ADAG) announced the appointment of Dr. John Maraganore as Executive Advisor. Maraganore was CEO of Alnylam from 2002 to 2021, where he led the Company through global approvals and commercialization of four RNA interference therapeutic medicines.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAG:
- Adagene’s Promising Clinical Developments and Strong Financial Outlook Justify Buy Rating
- Adagene Inc. Reports 2024 Financial Results and Progress
- Adagene Reports 2024 Financial Results and Advances Clinical Programs
- Adagene reports FY24 adjusted EPS (51c), consensus (58c)
- Adagene sees cash runway into late 2026
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue